en
Scientific article
English

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Published inThe Lancet HIV, vol. 4, no. 11, p. e486-e494
Publication date2017
Abstract

Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation.

Keywords
  • Administration
  • Oral
  • Adult
  • Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use
  • Biological Availability
  • Coinfection/virology
  • Double-Blind Method
  • Emtricitabine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
  • Female
  • HIV Infections/drug therapy/virology
  • HIV-1/drug effects/physiology
  • Hepatitis B/virology
  • Hepatitis C/virology
  • Humans
  • Male
  • Quality of Life
  • RNA
  • Viral/blood/drug effects
  • Raltegravir Potassium/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
  • Tenofovir/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
  • Viral Load/drug effects
Research group
Citation (ISO format)
CAHN, Pedro et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. In: The Lancet HIV, 2017, vol. 4, n° 11, p. e486–e494. doi: 10.1016/S2352-3018(17)30128-5
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal2352-3018
324views
0downloads

Technical informations

Creation11/06/2018 4:28:00 PM
First validation11/06/2018 4:28:00 PM
Update time03/15/2023 3:17:06 PM
Status update03/15/2023 3:17:04 PM
Last indexation05/03/2024 6:52:42 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack